New combo targets Hard-to-Treat cancers with gene mutations

NCT ID NCT05554380

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 6 times

Summary

This study tests whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel) can shrink or slow the growth of advanced solid tumors that have specific changes in the PTEN or AKT genes. About 33 adults whose cancer has spread or cannot be removed by surgery will receive both drugs. The goal is to see if this combination works better than chemotherapy alone for these genetic tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 33 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-S3 based on the presence of an actionable mutation as defined in EAY191 * GENERAL COMBOMATCH EAY191 REGISTRATION INCLUSION CRITERIA: * Participants must be enrolled on the ComboMATCH Master Registration Trial EAY191 * Participants must have an activating AKT mutation (a known mutation in AKT1, AKT2, or AKT3, a single nucleotide variant, insertion, or deletion), PTEN mutation (a known mutation in PTEN, a single nucleotide variant, insertion, or deletion), or genomic deletion loss of PTEN as determined by the ComboMATCH screening assessment * GENERAL COMBOMATCH EAY191 REGISTRATION EXCLUSION CRITERIA: * Participants must not have an activating KRAS, NRAS, HRAS, or BRAF mutation (a single nucleotide variant, insertion, or deletion) as determined by the ComboMATCH screening assessment * Participants must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191) * Participants must have a histologically confirmed non-breast solid malignancy * Participants must have locally advanced, unresectable, or metastatic disease in the opinion of the treating investigator * Participants must have measurable disease documented by CT or MRI. Measurable disease must be assessed within 28 days prior to registration. Non-measurable disease must be assessed within 42 days prior to registration. The CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1). Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration * Participants with known brain metastases must have a CT/MRI scan to evaluate for central nervous system (CNS) disease and show no evidence of progression within 42 days prior to registration * Participants must have completed any CNS-directed therapy and/or local therapy for spinal cord compression at least 28 days prior to registration * Participants must not have spinal cord compression or brain metastases unless: (1) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days prior to registration, AND (2) participant has no residual neurological dysfunction and has been off corticosteroids for at least 24 hours prior to registration * Participants must not have leptomeningeal disease * Participants must have progressed on or within 6 months of taxane-based therapy in the neoadjuvant/adjuvant or metastatic setting prior to registration * Participants must not have received any prior AKT inhibitor (e.g., capivasertib or ipatasertib); prior PI3K/mTOR inhibitor is acceptable * Participants must not have received cancer-directed therapy prior for at least 14 days prior to initiation of treatment on study * Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic, radiation, or hormonal therapy for cancer treatment while receiving treatment on this study * Participants must be \>= 18 years of age * Participants must be able to swallow oral medications whole * Participants must have a pre-study history and physical exam done within 28 days prior to registration * Participants must have a Zubrod performance status of 0-2 within 28 days prior to registration * Participants must have adverse events resolved =\< grade 1 related to any prior therapy, except alopecia within 14 days prior to registration * Participants with neuropathy must have resolved to \< grade 2 within 14 days prior to registration * Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to registration) * Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to registration) * Platelets \>= 100 x 10\^3/uL (within 28 days prior to registration) * Total bilirubin =\< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to registration) * Aspartate aminotransferase (AST) \& alanine aminotransferase (ALT) =\< 3 x institutional ULN (within 28 days prior to registration) * Participants must have adequate cardiac function, class IIB (2B) or better. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification * Participants must have a measured OR calculated creatinine clearance \>= 50 mL/min using the following Cockcroft-Gault formula. This specimen must have been drawn within 28 days prior to registration * Participants with known human immunodeficiency virus (HIV)-infection must be receiving anti-retroviral therapy and have an undetectable viral load test on the most recent test results obtained within 6 months prior to registration * Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy within 28 days prior to registration * Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment must have an undetectable HCV viral load within 28 days prior to registration * Participants must have an electrocardiography (ECG) performed (if clinically indicated with a corrected QTc interval of =\< 470 msec) within 28 days prior to registration * Participants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipatasertib and/or paclitaxel * Participants must not have an active small/large bowel inflammation such as ulcerative colitis or Crohn's disease * Participants must not have grade 2 or higher uncontrolled intercurrent illness * NOTE: To receive an agent, participant must not have any uncontrolled intercurrent illness requiring antibiotic/antiviral/antifungal therapy or interventional procedures. Participants with infections unlikely to be resolved within 2 weeks following registration should not be considered for the trial * Participants must not have a known grade 2 or higher uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia * Participants must not have any of the following: * Cirrhosis at a level of Child-Pugh B (or worse), * Cirrhosis (any degree) and a history of hepatic encephalopathy, or * Clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis * Participants must not be receiving any medications or substances that are inhibitors or inducers of CYP3A. Treatment with strong CYP3A inhibitors or strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug is prohibited. * NOTE: Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product. The participant wallet card should be presented to the participant * Participants must not have baseline fasting glucose (after 8-hour fast) \> 160 mg/dL (8.9 mmol/L) within 28 days prior to registration * Participants with known diabetes mellitus must not require insulin therapy or have a baseline fasting glucose \>150 mg/dL (8.3 mmol/L) or high glycosylated hemoglobin (Hb)A1c, (\>= 8.0%), suggesting poorly controlled diabetes * Participants who are on a stable dose of oral diabetes medication \>= 2 weeks prior to initiation of study drug treatment are eligible for enrollment * Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) must not have a potential to interfere with the safety or efficacy assessment of the investigational regimen * Participants must not have lung disease requiring active systemic therapy or placing participants at increased risk of toxicity related to study-directed therapy including, but not limited to pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia) * Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is of "reproductive potential". In addition to routine contraceptive methods, "effective contraception" also includes surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen * Participants must not have psychiatric illness/social situations that would limit compliance with study requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced malignant solid neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced malignant solid neoplasm Metastatic malignant solid neoplasm Unresectable malignant solid neoplasm

Contacts and locations

Locations

AMG Crystal Lake - Oncology

Crystal Lake, Illinois, 60014, United States
AMG Libertyville - Oncology

Libertyville, Illinois, 60048, United States
Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407, United States
Adena Regional Medical Center

Chillicothe, Ohio, 45601, United States
Advocate Christ Medical Center

Oak Lawn, Illinois, 60453-2699, United States
Advocate Good Samaritan Hospital

Downers Grove, Illinois, 60515, United States
Advocate Good Shepherd Hospital

Barrington, Illinois, 60010, United States
Advocate Illinois Masonic Medical Center

Chicago, Illinois, 60657, United States
Advocate Lutheran General Hospital

Park Ridge, Illinois, 60068, United States
Advocate Sherman Hospital

Elgin, Illinois, 60123, United States
Advocate South Suburban Hospital

Hazel Crest, Illinois, 60429, United States
Alaska Women's Cancer Care

Anchorage, Alaska, 99508, United States
Aultman Health Foundation

Canton, Ohio, 44710, United States
Aurora Bay Area Medical Group-Marinette

Marinette, Wisconsin, 54143, United States
Aurora BayCare Medical Center

Green Bay, Wisconsin, 54311, United States
Aurora Cancer Care-Grafton

Grafton, Wisconsin, 53024, United States
Aurora Cancer Care-Kenosha South

Kenosha, Wisconsin, 53142, United States
Aurora Cancer Care-Milwaukee

Milwaukee, Wisconsin, 53209, United States
Aurora Cancer Care-Milwaukee West

Wauwatosa, Wisconsin, 53226, United States
Aurora Cancer Care-Racine

Racine, Wisconsin, 53406, United States
Aurora Cancer Care-Southern Lakes VLCC

Burlington, Wisconsin, 53105, United States
Aurora Health Care Germantown Health Center

Germantown, Wisconsin, 53022, United States
Aurora Medical Center in Summit

Summit, Wisconsin, 53066, United States
Aurora Saint Luke's Medical Center

Milwaukee, Wisconsin, 53215, United States
Aurora Saint Luke's South Shore

Cudahy, Wisconsin, 53110, United States
Aurora Sinai Medical Center

Milwaukee, Wisconsin, 53233, United States
Aurora West Allis Medical Center

West Allis, Wisconsin, 53227, United States
Benefis Sletten Cancer Institute

Great Falls, Montana, 59405, United States
Billings Clinic Cancer Center

Billings, Montana, 59101, United States
Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715, United States
Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, 19010, United States
Cancer Hematology Centers - Flint

Flint, Michigan, 48503, United States
Carilion Roanoke Memorial Hospital

Roanoke, Virginia, 24033, United States
Carle Cancer Center

Urbana, Illinois, 61801, United States
Carle Physician Group-Effingham

Effingham, Illinois, 62401, United States
Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938, United States
Carle at The Riverfront

Danville, Illinois, 61832, United States
Case Western Reserve University

Cleveland, Ohio, 44106, United States
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Centro Comprensivo de Cancer de UPR

San Juan, 00927, Puerto Rico
Chelsea Hospital

Chelsea, Michigan, 48118, United States
Columbus Oncology and Hematology Associates

Dublin, Ohio, 43016, United States
Columbus Oncology and Hematology Associates Inc

Columbus, Ohio, 43214, United States
Community Hospital of Anaconda

Anaconda, Montana, 59711, United States
Community Medical Center

Missoula, Montana, 59804, United States
Condell Memorial Hospital

Libertyville, Illinois, 60048, United States
Corewell Health Beaumont Troy Hospital

Troy, Michigan, 48085, United States
Corewell Health Dearborn Hospital

Dearborn, Michigan, 48124, United States
Corewell Health Farmington Hills Hospital

Farmington Hills, Michigan, 48336, United States
Corewell Health William Beaumont University Hospital

Royal Oak, Michigan, 48073, United States
Dayton Physician LLC - Englewood

Dayton, Ohio, 45415, United States
Delaware Health Center-Grady Cancer Center

Delaware, Ohio, 43015, United States
Doctors Hospital

Columbus, Ohio, 43228, United States
Dublin Methodist Hospital

Dublin, Ohio, 43016, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Duluth Clinic Ashland

Ashland, Wisconsin, 54806, United States
Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636, United States
Essentia Health Cancer Center

Duluth, Minnesota, 55805, United States
Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746, United States
Essentia Health Sandstone

Sandstone, Minnesota, 55072, United States
Essentia Health Virginia Clinic

Virginia, Minnesota, 55792, United States
Fairfield Medical Center

Lancaster, Ohio, 43130, United States
Fairview Southdale Hospital

Edina, Minnesota, 55435, United States
Genesee Hematology Oncology PC

Flint, Michigan, 48503, United States
Genesis Healthcare System Cancer Care Center

Zanesville, Ohio, 43701, United States
Genesys Hurley Cancer Institute

Flint, Michigan, 48503, United States
Grady Memorial Hospital

Delaware, Ohio, 43015, United States
Grant Medical Center

Columbus, Ohio, 43215, United States
Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601, United States
Harold Alfond Center for Cancer Care

Augusta, Maine, 04330, United States
Henry Ford Saint John Hospital - Macomb Medical

Macomb, Michigan, 48044, United States
Hurley Medical Center

Flint, Michigan, 48503, United States
Huron Gastroenterology PC

Ypsilanti, Michigan, 48106, United States
Inova Fairfax Hospital

Falls Church, Virginia, 22042, United States
Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States
John H Stroger Jr Hospital of Cook County

Chicago, Illinois, 60612, United States
Kettering Medical Center

Kettering, Ohio, 45429, United States
Kingman Regional Medical Center

Kingman, Arizona, 86401, United States
Knox Community Hospital

Mount Vernon, Ohio, 43050, United States
Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854, United States
Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864, United States
Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814, United States
Lafayette Family Cancer Center-EMMC

Brewer, Maine, 04412, United States
Lankenau Medical Center

Wynnewood, Pennsylvania, 19096, United States
Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017, United States
Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103, United States
Lehigh Valley Hospital-Hazleton

Hazleton, Pennsylvania, 18201, United States
Licking Memorial Hospital

Newark, Ohio, 43055, United States
Logan Health Medical Center

Kalispell, Montana, 59901, United States
MaineHealth Maine Medical Center- Scarborough

Scarborough, Maine, 04074, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Memorial Hospital

Marysville, Ohio, 43040, United States
Mercy Health - Perrysburg Hospital

Perrysburg, Ohio, 43551, United States
Mercy Health - Saint Anne Hospital

Toledo, Ohio, 43623, United States
Mercy Hospital

Coon Rapids, Minnesota, 55433, United States
Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314, United States
Mount Carmel East Hospital

Columbus, Ohio, 43213, United States
Mount Sinai Hospital

New York, New York, 10029, United States
MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601, United States
MyMichigan Medical Center Tawas

Tawas City, Michigan, 48764, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Yakima, Washington, 98902, United States
OhioHealth Mansfield Hospital

Mansfield, Ohio, 44903, United States
OhioHealth Marion General Hospital

Marion, Ohio, 43302, United States
OhioHealth Westerville Medical Campus/Westerville Cancer Center

Westerville, Ohio, 43082, United States
Oncology Hematology Associates of Saginaw Valley PC

Saginaw, Michigan, 48604, United States
OptumCare Cancer Care at Charleston

Las Vegas, Nevada, 89102, United States
OptumCare Cancer Care at Fort Apache

Las Vegas, Nevada, 89183, United States
PCR Oncology

Arroyo Grande, California, 93420, United States
Paoli Memorial Hospital

Paoli, Pennsylvania, 19301, United States
Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416, United States
Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301, United States
Providence Newberg Medical Center

Newberg, Oregon, 97132, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Providence Saint Vincent Medical Center

Portland, Oregon, 97225, United States
Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045, United States
Puerto Rico Hematology Oncology Group

Bayamón, 00961, Puerto Rico
Rapid City Regional Hospital

Rapid City, South Dakota, 57701, United States
Regions Hospital

Saint Paul, Minnesota, 55101, United States
Riddle Memorial Hospital

Media, Pennsylvania, 19063, United States
Riverside Methodist Hospital

Columbus, Ohio, 43214, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706, United States
Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605, United States
Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687, United States
Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914, United States
Saint Ann's Hospital

Westerville, Ohio, 43081, United States
Saint John's Cancer Institute

Santa Monica, California, 90404, United States
Saint Joseph Hospital - Orange

Orange, California, 92868, United States
Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712, United States
Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619, United States
Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642, United States
Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687, United States
Saint Luke's Cancer Institute - Twin Falls

Twin Falls, Idaho, 83301, United States
Saint Mary's Oncology/Hematology Associates of West Branch

West Branch, Michigan, 48661, United States
Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501, United States
Sanford Broadway Medical Center

Fargo, North Dakota, 58122, United States
Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104, United States
Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601, United States
Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122, United States
Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134, United States
Southern Ohio Medical Center

Portsmouth, Ohio, 45662, United States
Springfield Regional Cancer Center

Springfield, Ohio, 45504, United States
Springfield Regional Medical Center

Springfield, Ohio, 45504, United States
Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304, United States
Strecker Cancer Center-Belpre

Belpre, Ohio, 45714, United States
Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026, United States
Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029, United States
Swedish Medical Center-First Hill

Seattle, Washington, 98122, United States
The Angeles Clinic and Research Institute - West Los Angeles Office

Los Angeles, California, 90025, United States
The Mark H Zangmeister Center

Columbus, Ohio, 43219, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States
Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114, United States
Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197, United States
Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114, United States
Trinity Health Medical Center - Canton

Canton, Michigan, 48188, United States
Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106, United States
Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341, United States
Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor, Ohio, 44060, United States
UH Seidman Cancer Center at UH Avon Health Center

Avon, Ohio, 44011, United States
UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, 44122, United States
UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny, Iowa, 50023, United States
UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309, United States
UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee, Iowa, 50263, United States
UM Sylvester Comprehensive Cancer Center at Aventura

Aventura, Florida, 33180, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables

Coral Gables, Florida, 33146, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442, United States
UM Sylvester Comprehensive Cancer Center at Kendall

Miami, Florida, 33176, United States
UM Sylvester Comprehensive Cancer Center at Plantation

Plantation, Florida, 33324, United States
UPMC Altoona

Altoona, Pennsylvania, 16601, United States
UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
UPMC Hillman Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146, United States
UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505, United States
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg, Pennsylvania, 17050, United States
UPMC Western Maryland

Cumberland, Maryland, 21502, United States
UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States
UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
United Hospital

Saint Paul, Minnesota, 55102, United States
University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136, United States
University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of South Alabama Mitchell Cancer Institute

Mobile, Alabama, 36688, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison, Wisconsin, 53718, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
VCU Community Memorial Health Center

South Hill, Virginia, 23970, United States
VCU Massey Cancer Center at Stony Point

Richmond, Virginia, 23235, United States
VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298, United States
Valley Medical Center

Renton, Washington, 98055, United States
Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh, Wisconsin, 54904, United States
Vince Lombardi Cancer Clinic-Sheboygan

Sheboygan, Wisconsin, 53081, United States
Vince Lombardi Cancer Clinic-Two Rivers

Two Rivers, Wisconsin, 54241, United States
Virginia Cancer Institute

Richmond, Virginia, 23229, United States
Women and Infants Hospital

Providence, Rhode Island, 02905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.